• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Drugs of today: Medicamentos de actualidad >Biosimilars for the treatment of infectious diseases: The case of biosimilar interferons.
【24h】

Biosimilars for the treatment of infectious diseases: The case of biosimilar interferons.

机译：用于治疗传染病的生物仿制药：以生物仿制药干扰素为例。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Biopharmaceuticals are the fastest-growing and the most expensive among prescription drugs. A biopharmaceutical drug can cost a patient between USD 25,000 and USD 120,000 a year. Such sophisticated medicines are critical options for many unmet medical needs where no sufficient therapies are available, and the demand for lower-cost biopharmaceuticals is tremendous. Biosimilars are similar to, but not the same as, innovative biopharmaceuticals. Since they are developed following patent expiration of innovative medicines, biosimilars represent a potentially lower-cost option to patients and healthcare providers. With a broad range of biopharmaceuticals going off patent, the biosimilars field became the focus of attention of drug developers, healthcare providers, patient advocate groups and politicians. Regulatory and marketing issues for biosimilars have been discussed in several recent reviews. The main focus of this article is the scientific spects of interferon-alpha biosimilars and next-generation interferons for the treatment of hepatitis C.
机译：生物药物是处方药中增长最快，最昂贵的药物。生物制药药物每年可使患者花费25,000美元至120,000美元。对于许多无法满足的医疗需求（如果没有足够的治疗方法），这种先进的药物是至关重要的选择，对低成本生物药物的需求也很大。生物仿制药与创新生物制药相似但不相同。由于生物仿制药是在创新药物专利到期后开发的，因此对于患者和医疗保健提供者而言，它们是一种潜在的低成本选择。随着广泛的生物制药专利申请失效，生物仿制药领域成为药物开发商，医疗保健提供者，患者权益倡导者团体和政客关注的焦点。最近几篇评论中都讨论了生物仿制药的监管和营销问题。本文的主要重点是用于治疗丙型肝炎的干扰素-α生物仿制药和下一代干扰素的科学领域。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号